‹ All Posts
SASI KUMAR SEBI RA

8th Aug · SEBI-Registered Analyst

Aarti Pharmalabs reported a strong Q1.

✦ Revenue: ₹535.8 Cr (+38.7% YoY) ✦ PBT: ₹101.1 Cr (+66.2% YoY) ✦ PAT: ₹76.1 Cr (+65.4% YoY) ✦ EPS: ₹8.40 (vs ₹5.08) Positives: ✦ Profit grew faster than sales. ✦ Profit margin improved to around 14.2% from 11.9% last year. ✦ The company's JV made a ₹7.4 Cr profit, compared with a ₹1.8 Cr loss last year. ✦ The board approved a 405 KL capacity expansion with an investment of around ₹149 Cr. Things to watch: ✦ Revenue was ₹582.6 Cr in Q4 FY26, so sales were lower compared to the previous quarter. ✦ The new expansion will be funded through the company's own money and borrowings. ✦ Aarti USA reported a small loss of around ₹0.25 Cr. Other updates: Rashesh C. Gogri is set to become Managing Director and Hetal Gogri Gala Executive Director from October 1, subject to shareholder approval. Last year's Q1 numbers were changed because of an FX derivative loss. This does not affect Q1 FY27 numbers or the company's equity.

#PersonalFinance#FundamentalViews#Post-ClosingCommentary#EquityResearch#StockInNews
897 likes·54 comments